NCT05880810 Continuous Glucose Monitor for Mayo Clinic Advanced Care at Home Patients
| NCT ID | NCT05880810 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Mayo Clinic |
| Condition | Diabetes Mellitus |
| Study Type | INTERVENTIONAL |
| Enrollment | 100 participants |
| Start Date | 2024-05-01 |
| Primary Completion | 2027-05 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
This trial targets 100 participants in total. It began in 2024-05-01 with a primary completion date of 2027-05.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
The purpose of this study is to measure differences in diabetes control with the use of continuous glucose monitor (CGM) and diabetes education compared with standard of care for glucose monitoring (glucometer checks) and diabetes education in participants with diabetes mellitus receiving therapy with insulin and being admitted to Mayo Clinic Advanced Care at Home Program (ACH).
Eligibility Criteria
Inclusion Criteria: * Patients who are admitted to Advanced Care at Home (ACH) Program and supposed to remain in ACH for at least 72 hours. * Patients with previous diagnosis of DM type 1 or type 2. * Patients taking subcutaneous (SQ) insulin either via multidose injections or SQ insulin pump. * Capable of giving signed informed consent Exclusion Criteria: * Actively treated for diabetes ketoacidosis (DKA) or hyperosmolar hyperglycemic state (HHS). * Participants taking acetaminophen more than 4g per day or more than 1gm every 6 hours. * Participants with altered mental status. * Participants diagnosed with dementia. * Patients with suicidal ideations or experiencing suicidal behavior. * Patients with liver cirrhosis. * Patients with End Stage Renal Disease on dialysis bot hemodialysis or peritoneal dialysis. * Participants with allergy to medical grade adhesive or medical tape. * Participants taking hydroxyurea. * Participants who are pregnant, wanting to become pregnant, or nursing during study period. * Patients with a planned MRI within the following 10 days after admission to ACH. * Participants currently using continuous glucose monitor (CGM) to dose insulin or check glucose level. * Participants with diabetes mellitus (DM) treated with diet alone. * Participants with DM treated with oral hypoglycemic medications. * Participants with DM treated with one SQ insulin injection daily. * Participants enrolled in other studies addressing CGM use. * Participants physically or emotionally incapable of handling a cell phone with a smart display. * Participants with hearing impaired to a degree that they are not able to hear a smart phone alert or alarm. * Patients lacking WIFI or Cellular coverage needed to connect the monitoring cell phone to Internet network.
Contact & Investigator
Adrian Dumitrascu, MD
PRINCIPAL INVESTIGATOR
Mayo Clinic
Frequently Asked Questions
Who can join the NCT05880810 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, studying Diabetes Mellitus. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT05880810 currently recruiting?
Yes, NCT05880810 is actively recruiting participants. Visit ClinicalTrials.gov or contact Mayo Clinic to inquire about joining.
Where is the NCT05880810 trial being conducted?
This trial is being conducted at Jacksonville, United States.
Who is sponsoring the NCT05880810 clinical trial?
NCT05880810 is sponsored by Mayo Clinic. The principal investigator is Adrian Dumitrascu, MD at Mayo Clinic. The trial plans to enroll 100 participants.
Related Trials
Related Intelligence Guides
In-depth guides covering this condition's trials, eligibility, and what to expect.